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Sexual dysfunction is commonly reported by patients with
epilepsy, the prevalence is not clearly deﬁned and is different by
gender. Although older studies found higher frequencies, studies
with structured interviews reported the prevalence to be 20% in
male patients and 20–30% in female patients.1,2 The most frequent
epilepsy associated sexual dysfunctions are decreased libido and
potency problems in men and hyposexuality and orgasmic
dysfunction in women.1,2
Many hormones of the hypothalamic–pituitary axis related to
sexual functions are affected in patients with epilepsy. Antiepi-
leptic drugs such as carbamazepine and phenytoine are enzyme
inducers which cause reduction in the levels of testosterone in men
and estrogens in women and contribute to sexual dysfunction.3
Lamotrigine and levetiracetam, which are neither enzyme inducers
nor enzyme inhibitors, have been shown to improve sexual
functioning in persons with epilepsy.4 Speciﬁcally, female patients
with epilepsy aged 18–45 treated with levetiracetam reported
greater satisfaction with their sexual lives when compared to those
who were treated with carbamazepine or even healthy controls.4
The focal epileptic discharges appear to play a role in sexual
dysfunction.1 Daniele et al. reported a reduction of sexual interest
in patients with right-sided temporal lobe epilepsy (R-TLE) as
compared with left-sided temporal epilepsy (L-TLE) and discussed* Corresponding author. Tel.: +90 2124143128; fax: +90 2124143000/21239.
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may contribute to the different patterns of pituitary gonadotropin
secretion.5
Hypersexuality is a relatively rare sexual dysfunction in
epileptic patients. There are three reported cases of antiepileptic
drug induced hypersexuality: one case of mania with hypersexu-
ality induced by carbamazepine and two cases of hypersexuality
without manic or hypomanic features induced by adjunctive
lamotrigine to carbamazepine and oxcarbazepine.6,7 We report a
female patient who exhibited acute hypersexuality with the
addition of levetiracetam while taking carbamazepine. To our
knowledge this is the ﬁrst reported case of hypersexuality
triggered by levetiracetam.
2. Case
The patient was a 44 year-old woman with a history of mesial
temporal lobe epilepsy since she was 15. Her lesion was surgically
removed 13 years ago, pathology revealed a ganglioglioma. After
being seizure free for 5 years, the patient had 1–2 seizures monthly
while being treated with carbamazepine. Her last EEG in 2008
revealed left fronto-temporal epileptiform activity. Her MRI in
2009 noted left and temporo-occipital post-operative encephalo-
malacia. She had one depressive episode following her divorce 15
years ago, at which time she attempted to commit suicide with her
anticonvulsant pills. She had partial response to pharmacotherapy.
Her depressive features eventually resolved when she returned to
work a few years ago. She had no sexual dysfunction her entire life
and no sexual intercourse after her divorce. She masturbated 3–4
times a year for a few days when she was attracted by someone.
After the patient developed osteoporosis, levetiracetam was
initiated at 500 mg/day and titrated to 2000 mg/day while
carbamazepine was decreased from 1000 to 800 mg/day. Three
days after the initiation of 2000 mg/day, she experienced increased
sexual drive without being stimulated visually or tactilely. She
developed sexual daydreams and started to masturbate 8–9 times/
day. She determined these experiences as unpleasant and
disturbing. After reporting about her new sexual complaints to
her long-standing epileptologist, levetiracetam was decreased and
psychiatric consultation was requested. Whereas the psychiatric
diagnostic interview suggested a prior major depressive episode or
adjustment disorder with depressed mood at time of the priorvier Ltd. All rights reserved.
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denial of all manic or hypomanic features including hypersexuali-
ty. Further, the patient had no prior or current medical history,
including brain injuries, which could have predisposed her to
hypersexuality excluding epilepsy and remote temporal lobecto-
my. Therefore levatirecetam was suspected as the causative factor.
With gradual reduction of the levetiracetam dosage down to
1000 mg/day, her masturbation frequency decreased to 2–3 times
a day and disappeared with discontinuation of the drug. The
patient is now treated with carbamazepine 800 mg/day and has
been seizure-free for 4 months and her sexual desire and activity
returned to baseline.
3. Discussion
Hypersexuality is an excessive drive in frequency and intensity
for an individual to engage in reccurent sexually arousing fantasies,
sexual urges, or behaviors.8 It is reported as a result of organic
disorders such as dementia, stroke, brain injury, temporal lobe
epilepsy, epilepsy surgery, treatment with stimulant drugs like
methamphetamine and cocaine or dopaminergic treatment for
Parkinson’s Disease, moclobemide and bupropion.9 It is a well
known symptom of bipolar mania and antidepressant treatment
may also induce manic switch in depressive patients, causing
hypersexuality.10
Our patient did not meet any of the etiological causes cited
above. Speciﬁcally, she was not having a hypomanic or manic
episode, was not being treated with stimulants or antidepressant
psychotropics and did not have history of neurologic disease
associated with hypersexuality excluding epilepsy with her left-
sided remote temporal lobectomy. As mentioned above, R-TLE is a
greater risk factor for sexual dysfunction compared to L-TLE, and
sexual dysfunction tends to resolve after surgical resection.5,11
There are other case reports of hypersexuality after epilepsy
surgery.12 To our knowledge, there is no data suggesting a
tendency for hypersexuality in patients with L-TLE and a review by
Suffren et al. suggested that hypersexuality more often resulted
from right hemisphere than left hemisphere lesions.13 The onset of
hypersexuality in our patient was temporarily related to the
initiation of levetiracetam and resolved when it was discontinued.
Therefore the authors concluded that hypersexuality was induced
by levetiracetam.
Levetiracetam is an anticonvulsant with unique neuromodulary
and neuroinhibitory properties. It binds to synaptic vesicle protein
2A, opposes the activity of negative modulators of GABA and
inhibits N-type calcium channels.14 Levetiracetam treatment has
not been reported to cause any drug-speciﬁc sexual or endocrine
side effects in men or women. It has also been reported to improve
sexual function in women.4
A recent original research suggested that genetic variation of
dopaminergic activity in patients might predispose to psychiatriccomplications under treatment with levetiracetam.15 Dopamine is
a neurotransmitter that has been implicated in human and animal
sexual behavior and is believed to be the core of the excitatory
neurotransmitter of sexual desire.16 In our patient, hypersexuality
might be triggered via dopamine pathways as in the cases of
irritability and aggression. Since levetiracetam is believed to
enhance the activity of GABA and GABAergic pathways are known
to be a part of inhibitory system for sexual behavior,16 this
neurotransmitter is less likely to be involved in hypersexuality in
this patient.
This is a record of a single case, more elaborative clinical studies
are needed to assess the actual prevalence of this phenomenon
among patients treated with levetiracetam. Clinicians should
consider this adverse effect and the patient’s sexual state when
choosing levetiracetam in the treatment of epilepsy or in the off-
label treatment of multiple psychiatric disorders.
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